The purpose of the study is to evaluate how effective cabergoline is in treating non-functioning pituitary adenomas. Participants in the study will be randomly assigned to receive either cabergoline or a placebo. The study will last for two years, during which time the size of the tumor will be monitored using MRI scans. The researchers will be looking for changes in the tumor’s size, including any shrinkage or growth, and will also assess whether there is a need for additional treatments like surgery or radiation.

Throughout the study, the researchers will also monitor for any changes in pituitary function, which is the gland’s ability to produce hormones, as well as any changes in vision or other nerve functions. The study aims to provide valuable information on whether cabergoline can be an effective treatment option for people with non-functioning pituitary adenomas.